Safety signal hub
Metabolic peptide safety signal hub
Curated hub of metabolic peptide safety signals: GI events, pancreatitis, gallbladder disease, diabetic retinopathy, thyroid C-cell warning, hypoglycaemia, psychiatric signal tracking, pregnancy / breastfeeding, lean-mass / nutritional risk, dehydration / renal risk and counterfeit-product risk.
Each signal page documents what is known, what remains uncertain, the trial limitations, and the UK clinical / pharmacovigilance framing — alongside firm reminders that this site does not provide individual triage. Persistent or severe symptoms warrant qualified clinical assessment, not an internet page.
Well-characterised class effect
GLP-1 class gastrointestinal adverse events
Nausea, diarrhoea, constipation, vomiting and abdominal pain are the most common adverse events reported with GLP-1 receptor agonists and dual / triple agonists. They tend to be mild-to-moderate, concentrated during titration, and improve over time, but are also the leading reason for treatment discontinuation in trials.
Monitored signal, evolving evidence
Pancreatitis signal
Acute pancreatitis has been reported in association with GLP-1 receptor agonists since the earliest agents in the class. Pivotal trials and post-marketing surveillance describe a small but non-zero rate, the signal continues to be monitored, and personal or family history of pancreatitis is a contraindication or warning in the licensed product information for the major agents.
Well-characterised class effect
Gallbladder disease in the context of rapid weight reduction
Cholelithiasis and cholecystitis events have been reported more frequently with GLP-1 receptor agonists than placebo in pivotal trials, consistent with the well-known association between rapid weight loss and gallstone formation.
Monitored signal, evolving evidence
Diabetic retinopathy and rapid HbA1c reduction
Rapid HbA1c reduction in adults with pre-existing diabetic retinopathy has been associated with transient worsening of retinopathy in some trials. The SUSTAIN 6 cardiovascular outcomes trial of semaglutide reported an imbalance in retinopathy complications and prompted ongoing investigation.
Monitored signal, evolving evidence
Thyroid C-cell warning explained
GLP-1 receptor agonist labelling carries a boxed warning (US FDA) regarding medullary thyroid carcinoma based on rodent C-cell tumour findings. Translation to humans remains uncertain; long-term human evidence has not established a causal association.
Well-characterised class effect
Hypoglycaemia risk by drug class
On their own, GLP-1 receptor agonists at licensed doses cause hypoglycaemia infrequently because their insulinotropic effect is glucose-dependent. Risk rises substantially when combined with insulin or sulfonylureas.
Active pharmacovigilance review
Psychiatric adverse-event signal tracking
Concerns about mood-related and suicidality signals with GLP-1 receptor agonists have been the subject of EMA and FDA reviews. Current published reviews have not established a causal psychiatric safety signal but active pharmacovigilance continues.
Well-characterised class effect
Pregnancy and breastfeeding exclusions
Licensed incretin medicines are not recommended in pregnancy or breastfeeding in their UK SmPCs. Trials systematically exclude pregnant and breastfeeding participants.
Well-characterised class effect
Injection-site reactions in clinical trials
Injection-site reactions (erythema, induration, pruritus) are common with subcutaneous peptide therapies but are typically mild and self-limiting in pivotal trials.
Monitored signal, evolving evidence
Lean-mass and nutritional risk during rapid weight reduction
Substantial weight reduction with incretin therapy includes loss of lean mass alongside fat mass. In older adults, sarcopenic obesity, and those with limited protein intake, the lean-mass dimension warrants explicit attention.
Well-characterised class effect
Dehydration and renal risk
Severe vomiting or diarrhoea on incretin therapy can precipitate dehydration, which may worsen renal function — particularly in those with pre-existing chronic kidney disease, on diuretics, or on RAAS-acting medicines.
Risk associated with product quality / supply chain
Counterfeit and unregulated products
Counterfeit weight-loss pens, mislabelled vials and grey-market compounded products have been the subject of MHRA enforcement and public warnings. Risks include unknown identity, purity, sterility, dosing accuracy and the absence of regulated pharmacovigilance.
Conversational reference
GLP-1 specific side effects — A to Z →
Alphabetised symptom-by-symptom FAQ for the "does X cause Y" queries patients commonly ask. Each entry links to the detailed signal page where one exists.
Conversational reference
GLP-1 medicines and pregnancy →
SmPC contraindications, washout evidence and prescriber-led planning.
Conversational reference
GLP-1 medicines and alcohol →
Appetitive-signal changes, GI-tolerability interaction and safety framing.
Conversational reference
GLP-1 medicines and lean mass →
DXA/MRI body-composition sub-studies and what they do and do not establish.
Conversational reference
GLP-1 medicines and bone health →
STEP and SURMOUNT DXA bone-density sub-studies and the older-adult fracture-risk overlay.
Conversational reference
GLP-1 medicines and drug interactions →
What UK SmPCs say about levothyroxine, warfarin, oral contraceptives, insulin and DOACs.
Conversational reference
GLP-1 medicines and mental health →
MHRA and FDA class-monitoring positions on mood, depression and suicidality signals.
Conversational reference
GLP-1 medicines and surgery →
ASA and UK Centre for Perioperative Care guidance on gastric emptying and aspiration risk.
Conversational reference
GLP-1 medicines and rapid discontinuation →
STEP-4 and SURMOUNT-4 withdrawal-arm data on weight regain after stopping.
Curated dashboard
Safety signal dashboard →
Single-page view of all 12 safety signals with maturity badges, implicated molecule classes and links to detailed pages.
- It does not triage individual symptoms — that is the role of qualified clinical care.
- It does not provide dosing, titration or discontinuation advice.
- It does not list or rank suppliers.
- It does not displace MHRA Yellow Card reporting for the licensed medicines.